Brought to you by 
Cytogen's CytoRad (therap. and diag.) raises $32.5M in IPO
13 Jul 1999
Executive Summary
Cytogen completed an IPO for CytoRad, its new spin-off which will concentrate on the development of four therapeutic and diagnostic products for prostate and bladder cancer. 3.5 million units were sold at $10 each, raising $32.5 million for CytoRad.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cytogen's CytoRad (therap. and diag.) raises $32.5M in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice